
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
All Stakeholders in Human Research Protection Would Benefit from a Cooperative Enterprise That Moves Forward Without Blame






